Understandable that the market is reading no superiority to...

Understandable that the market is reading no superiority to Epidiolex as a disappointment. I too would have liked to see some superiority data and we were primed a little to hope for that. Objectively this announcement has been downgraded from “amazing” to merely “very positive”. It’s the market perception that matters for short term price, but this isn’t going to affect registration prospects or, in my opinion, ultimate marketability.

My read - This data is great. It’s safe, it’s as good as the only currently approved drug, it’s going to be OTC, it’s a more convenient dosing form. People prefer pills to oils.